{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:51:36Z","timestamp":1773413496536,"version":"3.50.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00763-0","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:26:09Z","timestamp":1761351969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-7005","authenticated-orcid":false,"given":"Nickolas","family":"Steinauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"763_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"763_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99:1142\u201365.","journal-title":"Am J Hematol"},{"key":"763_CR3","first-page":"22","volume":"110","author":"L Marando","year":"2025","unstructured":"Marando L, Csizmar CM, Patnaik MM. Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations. Haematologica. 2025;110:22\u201336.","journal-title":"Haematologica"},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrm.2017.27","volume":"18","author":"FE Baralle","year":"2017","unstructured":"Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18:437\u201351.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41576-022-00514-4","volume":"23","author":"CJ Wright","year":"2022","unstructured":"Wright CJ, Smith CWJ, Jiggins CD. Alternative splicing as a source of phenotypic diversity. Nat Rev Genet. 2022;23:697\u2013710.","journal-title":"Nat Rev Genet"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczuk\u00f3w O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23:135\u201355.","journal-title":"Nat Rev Cancer"},{"key":"763_CR7","doi-asserted-by":"crossref","unstructured":"Choquet K, Patop IL, Churchman LS. (2025) The regulation and function of post-transcriptional RNA splicing. Nat Rev Genet 1\u201317.","DOI":"10.1038\/s41576-025-00836-z"},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-biochem-091719-064225","volume":"89","author":"ME Wilkinson","year":"2020","unstructured":"Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu Rev Biochem. 2020;89:359\u201388.","journal-title":"Annu Rev Biochem"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u20139.","journal-title":"Nature"},{"key":"763_CR10","first-page":"584","volume":"130","author":"V Adema","year":"2017","unstructured":"Adema V, Hirsch CM, Przychodzen BP, et al. Somatic PRPF8 mutations in myeloid neoplasia. Blood. 2017;130:584.","journal-title":"Blood"},{"key":"763_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1182\/blood-2016-10-692400","volume":"129","author":"B Saez","year":"2017","unstructured":"Saez B, Walter MJ, Graubert TA. Splicing factor gene mutations in hematologic malignancies. Blood. 2017;129:1260\u20139.","journal-title":"Blood"},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1182\/blood.2019004260","volume":"138","author":"S Chen","year":"2021","unstructured":"Chen S, Benbarche S, Abdel-Wahab O. Splicing factor mutations in hematologic malignancies. Blood. 2021;138:599\u2013612.","journal-title":"Blood"},{"key":"763_CR13","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood.2020006868","volume":"136","author":"J Taylor","year":"2020","unstructured":"Taylor J, Mi X, North K, et al. Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood. 2020;136:1477\u201386.","journal-title":"Blood"},{"key":"763_CR14","first-page":"1032","volume":"135","author":"J Pangallo","year":"2020","unstructured":"Pangallo J, Kiladjian J-J, Cassinat B, Renneville A, Taylor J, Polaski JT, North K, Abdel-Wahab O, Bradley RK. Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood. 2020;135:1032\u201343.","journal-title":"Blood"},{"key":"763_CR15","first-page":"E4726","volume":"112","author":"J Zhang","year":"2015","unstructured":"Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, Raza A, Mukherjee S, Manley JL. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci. 2015;112:E4726\u201334.","journal-title":"Proc Natl Acad Sci"},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia through Mutant-Specific effects on exon recognition. Cancer Cell. 2015;27:617\u201330.","journal-title":"Cancer Cell"},{"key":"763_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","volume":"13","author":"RB Darman","year":"2015","unstructured":"Darman RB, Seiler M, Agrawal AA, et al. Cancer-Associated SF3B1 hotspot mutations induce cryptic 3\u2032 splice site selection through use of a different branch point. Cell Rep. 2015;13:1033\u201345.","journal-title":"Cell Rep"},{"key":"763_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1101\/gr.181016.114","volume":"25","author":"JO Ilagan","year":"2015","unstructured":"Ilagan JO, Ramakrishnan A, Hayes B, Murphy ME, Zebari AS, Bradley P, Bradley RK. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25:14\u201326.","journal-title":"Genome Res"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/leu.2014.303","volume":"29","author":"T Okeyo-Owuor","year":"2015","unstructured":"Okeyo-Owuor T, White BS, Chatrikhi R, et al. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia. 2015;29:909\u201317.","journal-title":"Leukemia"},{"key":"763_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27086","author":"A Ferrer","year":"2023","unstructured":"Ferrer A, Lasho T, Fernandez JA, et al. Patients with telomere biology disorders show context specific somatic mosaic States with high frequency of U2AF1 variants. Am J Hematol. 2023. https:\/\/doi.org\/10.1002\/ajh.27086.","journal-title":"Am J Hematol"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00922-7","volume":"13","author":"T Badar","year":"2023","unstructured":"Badar T, Vanegas YAM, Nanaa A, et al. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer J. 2023;13:1\u20137.","journal-title":"Blood Cancer J"},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1101\/gad.1974810","volume":"24","author":"H Shen","year":"2010","unstructured":"Shen H, Zheng X, Luecke S, Green MR. The U2AF35-related protein urp contacts the 3\u2019 splice site to promote U12-type intron splicing and the second step of U2-type intron splicing. Genes Dev. 2010;24:2389\u201394.","journal-title":"Genes Dev"},{"key":"763_CR23","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1038\/ncomms7042","volume":"6","author":"V Madan","year":"2015","unstructured":"Madan V, Kanojia D, Li J, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun. 2015;6:6042.","journal-title":"Nat Commun"},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood.2023022222","volume":"142","author":"LD Weeks","year":"2023","unstructured":"Weeks LD, Ebert BL. Causes and consequences of clonal hematopoiesis. Blood. 2023;142:2235\u201346.","journal-title":"Blood"},{"key":"763_CR25","doi-asserted-by":"publisher","unstructured":"Mangaonkar AA, Patnaik MM. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26915","DOI":"10.1002\/ajh.26915"},{"key":"763_CR26","doi-asserted-by":"publisher","first-page":"107007","DOI":"10.1016\/j.leukres.2022.107007","volume":"125","author":"SL Pritzl","year":"2023","unstructured":"Pritzl SL, Gurney M, Badar T, et al. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective Mayo clinic cohort study. Leuk Res. 2023;125:107007.","journal-title":"Leuk Res"},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400\u20134.","journal-title":"Nature"},{"key":"763_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","volume":"606","author":"MA Fabre","year":"2022","unstructured":"Fabre MA, de Almeida JG, Fiorillo E, et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022;606:335\u201342.","journal-title":"Nature"},{"key":"763_CR29","doi-asserted-by":"publisher","first-page":"106818","DOI":"10.1016\/j.leukres.2022.106818","volume":"116","author":"Z Xie","year":"2022","unstructured":"Xie Z, Campestri G, Lasho T, et al. Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. Leuk Res. 2022;116:106818.","journal-title":"Leuk Res"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/blood-2017-01-762393","volume":"131","author":"A Kon","year":"2018","unstructured":"Kon A, Yamazaki S, Nannya Y, et al. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood. 2018;131:621\u201335.","journal-title":"Blood"},{"key":"763_CR31","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","volume":"34","author":"G Coltro","year":"2020","unstructured":"Coltro G, Mangaonkar AA, Lasho TL, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)\u2014a study of 1084 patients. Leukemia. 2020;34:1407\u201321.","journal-title":"Leukemia"},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S, et al. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood. 2020;136:1851\u201362.","journal-title":"Blood"},{"key":"763_CR33","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","volume":"121","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121:2186\u201398.","journal-title":"Blood"},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/10428194.2024.2432581","volume":"66","author":"SG Cockey","year":"2025","unstructured":"Cockey SG, Zhang H, Hussaini M, Zhang L, Moscinski L, Yang E, Li J, Wang L, Song J. Molecular landscape and clinical outcome of SRSF2\/TET2 Co-mutated myeloid neoplasms. Leuk Lymphoma. 2025;66:469\u201378.","journal-title":"Leuk Lymphoma"},{"key":"763_CR35","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1038\/s41375-020-01106-z","volume":"35","author":"G Todisco","year":"2021","unstructured":"Todisco G, Creignou M, Gall\u00ec A, et al. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia. 2021;35:2371\u201381.","journal-title":"Leukemia"},{"key":"763_CR36","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","volume":"120","author":"M Meggendorfer","year":"2012","unstructured":"Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120:3080\u20138.","journal-title":"Blood"},{"key":"763_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/path.6396","volume":"265","author":"H-W Kao","year":"2025","unstructured":"Kao H-W, Kuo M-C, Ou C-W, Huang T-Y, Chang H, Lin T-L, Hung Y-S, Wu J-H, Shih L-Y. Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison. J Pathol. 2025;265:437\u201347.","journal-title":"J Pathol"},{"key":"763_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/ejh.13768","volume":"109","author":"K Geissler","year":"2022","unstructured":"Geissler K, J\u00e4ger E, Barna A, et al. Multistep pathogenesis of chronic myelomonocytic leukemia in patients. Eur J Haematol. 2022;109:50\u20137.","journal-title":"Eur J Haematol"},{"key":"763_CR39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjh.19060","volume":"203","author":"G Montalban-Bravo","year":"2023","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Li Z, et al. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023;203:581\u201392.","journal-title":"Br J Haematol"},{"key":"763_CR40","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1182\/blood-2018-04-845602","volume":"132","author":"MF Smeets","year":"2018","unstructured":"Smeets MF, Tan SY, Xu JJ, et al. Srsf2P95H initiates myeloid bias and myelodysplastic\/myeloproliferative syndrome from Hemopoietic stem cells. Blood. 2018;132:608\u201321.","journal-title":"Blood"},{"key":"763_CR41","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1038\/s41375-022-01727-6","volume":"36","author":"JJ Xu","year":"2022","unstructured":"Xu JJ, Chalk AM, Wall M, Langdon WY, Smeets MF, Walkley CR. Srsf2P95H\/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice. Leukemia. 2022;36:2883\u201393.","journal-title":"Leukemia"},{"key":"763_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-019-1618-0","volume":"574","author":"A Yoshimi","year":"2019","unstructured":"Yoshimi A, Lin K-T, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574:273\u20137.","journal-title":"Nature"},{"key":"763_CR43","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1016\/j.molcel.2023.11.003","volume":"83","author":"H-L Ma","year":"2023","unstructured":"Ma H-L, Bizet M, Soares Da Costa C, et al. SRSF2 plays an unexpected role as reader of m5C on mRNA, linking epitranscriptomics to cancer. Mol Cell. 2023;83:4239\u2013e425410.","journal-title":"Mol Cell"},{"key":"763_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature25434","volume":"554","author":"Q Shen","year":"2018","unstructured":"Shen Q, Zhang Q, Shi Y, et al. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation. Nature. 2018;554:123\u20137.","journal-title":"Nature"},{"key":"763_CR45","doi-asserted-by":"publisher","first-page":"e15743","DOI":"10.1097\/MD.0000000000015743","volume":"98","author":"X Wang","year":"2019","unstructured":"Wang X, Song X, Yan X. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis. Med (Baltim). 2019;98:e15743.","journal-title":"Med (Baltim)"},{"key":"763_CR46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103283","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011. https:\/\/doi.org\/10.1056\/NEJMoa1103283.","journal-title":"N Engl J Med"},{"key":"763_CR47","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"763_CR48","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"763_CR49","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood.2023020649","volume":"142","author":"J Senapati","year":"2023","unstructured":"Senapati J, Urrutia S, Loghavi S, et al. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023;142:1647\u201357.","journal-title":"Blood"},{"key":"763_CR50","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"763_CR51","doi-asserted-by":"publisher","unstructured":"Rana MS, Iftikhar M, Jadoon Y, Abdelmagid M, Viswanatha DS, He R, Reichard KK, Pardanani AD, Gangat N. Tefferi A the mutational landscape in polycythemia vera: Phenotype, Genotype, and prognostic correlates. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27717","DOI":"10.1002\/ajh.27717"},{"key":"763_CR52","doi-asserted-by":"publisher","unstructured":"Xicoy B, Pomares H, Morgades M, et al. Chronic myelomonocytic leukemia with ring sideroblasts\/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS\/SF3B1 mutation in terms of phenotype and prognosis. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1385987.","DOI":"10.3389\/fonc.2024.1385987"},{"key":"763_CR53","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1182\/bloodadvances.2020001972","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Loghavi S, Mangaonkar AA, et al. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia\u2013free survival. Blood Adv. 2020;4:5716\u201321.","journal-title":"Blood Adv"},{"key":"763_CR54","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27:1504\u201310.","journal-title":"Leukemia"},{"key":"763_CR55","doi-asserted-by":"publisher","unstructured":"P AJ, H A, R S, M S, A A. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. Hematol Amst Neth. 2018. https:\/\/doi.org\/10.1080\/10245332.2018.1471794.","DOI":"10.1080\/10245332.2018.1471794"},{"key":"763_CR56","doi-asserted-by":"publisher","first-page":"107565","DOI":"10.1016\/j.leukres.2024.107565","volume":"145","author":"A Desai","year":"2024","unstructured":"Desai A, Samara Y, Yang D, et al. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024;145:107565.","journal-title":"Leuk Res"},{"key":"763_CR57","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3324\/haematol.2021.280203","volume":"108","author":"M Mei","year":"2023","unstructured":"Mei M, Pillai R, Kim S, et al. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a center for blood and marrow transplantation research (CIBMTR) analysis. Haematologica. 2023;108:150\u201360.","journal-title":"Haematologica"},{"key":"763_CR58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajh.23373","volume":"88","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013;88:201\u20136.","journal-title":"Am J Hematol"},{"key":"763_CR59","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.1182\/blood-2024-205576","volume":"144","author":"J Bai","year":"2024","unstructured":"Bai J, Qiu C, Yao M, Deng C, Li M, Geng S, Huang J, Chen Y, Zhou Y, Du X. SRSF2 mutation cooperates with ASXL1 mutation to promote the development of myeloproliferative variant of chronic myelomonocytic leukemia. Blood. 2024;144:6690.","journal-title":"Blood"},{"key":"763_CR60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41375-023-02094-6","volume":"38","author":"P Sui","year":"2024","unstructured":"Sui P, Ge G, Chen S, et al. SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis. Leukemia. 2024;38:408\u201311.","journal-title":"Leukemia"},{"key":"763_CR61","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","volume":"120","author":"S-J Wu","year":"2012","unstructured":"Wu S-J, Kuo Y-Y, Hou H-A, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120:3106\u201311.","journal-title":"Blood"},{"key":"763_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25673","volume":"95","author":"V Madan","year":"2020","unstructured":"Madan V, Li J, Zhou S, et al. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. Am J Hematol. 2020;95:133\u201343.","journal-title":"Am J Hematol"},{"key":"763_CR63","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","volume":"574","author":"D Inoue","year":"2019","unstructured":"Inoue D, Chew G-L, Liu B, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574:432\u20136.","journal-title":"Nature"},{"key":"763_CR64","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1038\/s41375-022-01672-4","volume":"36","author":"BA Wang","year":"2022","unstructured":"Wang BA, Mehta HM, Penumutchu SR, Tolbert BS, Cheng C, Kimmel M, Haferlach T, Maciejewski JP, Corey SJ. Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms. Leukemia. 2022;36:2499\u2013508.","journal-title":"Leukemia"},{"key":"763_CR65","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2021012652","volume":"139","author":"CA Clough","year":"2022","unstructured":"Clough CA, Pangallo J, Sarchi M, et al. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood. 2022;139:2038\u201349.","journal-title":"Blood"},{"key":"763_CR66","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.stem.2023.07.012","volume":"30","author":"M Cort\u00e9s-L\u00f3pez","year":"2023","unstructured":"Cort\u00e9s-L\u00f3pez M, Chamely P, Hawkins AG, et al. Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell Stem Cell. 2023;30:1262\u2013e12818.","journal-title":"Cell Stem Cell"},{"key":"763_CR67","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.jbior.2024.101055","volume":"95","author":"A Pellagatti","year":"2025","unstructured":"Pellagatti A, Boultwood J. Hyperactivation of NF-\u03baB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches. Adv Biol Regul. 2025;95:101055.","journal-title":"Adv Biol Regul"},{"key":"763_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2018.07.003","volume":"34","author":"SC-W Lee","year":"2018","unstructured":"Lee SC-W, North K, Kim E, et al. Synthetic lethal and convergent biological effects of Cancer-Associated spliceosomal gene mutations. Cancer Cell. 2018;34:225\u2013e2418.","journal-title":"Cancer Cell"},{"key":"763_CR69","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","volume":"21","author":"MA Smith","year":"2019","unstructured":"Smith MA, Choudhary GS, Pellagatti A, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019;21:640\u201350.","journal-title":"Nat Cell Biol"},{"key":"763_CR70","doi-asserted-by":"publisher","first-page":"e78136","DOI":"10.7554\/eLife.78136","volume":"11","author":"GS Choudhary","year":"2022","unstructured":"Choudhary GS, Pellagatti A, Agianian B, et al. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. eLife. 2022;11:e78136.","journal-title":"eLife"},{"key":"763_CR71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025670","author":"K Takashima","year":"2025","unstructured":"Takashima K, Olszewska M, Jethalia V, Sirenko M, Silverman L, Tomalin LE, Carcamo S, Hasson D, Papapetrou EP. Cell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem\/progenitor cells. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024025670.","journal-title":"Blood"},{"key":"763_CR72","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2022.12.001","volume":"33","author":"S Avagyan","year":"2023","unstructured":"Avagyan S, Zon LI. Clonal hematopoiesis and inflammation \u2013 the perpetual cycle. Trends Cell Biol. 2023;33:695\u2013707.","journal-title":"Trends Cell Biol"},{"key":"763_CR73","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","volume":"12","author":"K Togami","year":"2022","unstructured":"Togami K, Chung SS, Madan V, et al. Sex-Biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 2022;12:522\u201341.","journal-title":"Cancer Discov"},{"key":"763_CR74","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrg3961","volume":"16","author":"JM Santos-Pereira","year":"2015","unstructured":"Santos-Pereira JM, Aguilera A. R loops: new modulators of genome dynamics and function. Nat Rev Genet. 2015;16:583\u201397.","journal-title":"Nat Rev Genet"},{"key":"763_CR75","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/0008-5472.CAN-23-3239","volume":"84","author":"ZS Liu","year":"2024","unstructured":"Liu ZS, Sinha S, Bannister M, et al. R-Loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 Inhibition by triggering Transcription-Replication conflicts. Cancer Res. 2024;84:577\u201397.","journal-title":"Cancer Res"},{"key":"763_CR76","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","volume":"78","author":"HD Nguyen","year":"2018","unstructured":"Nguyen HD, Leong WY, Li W, Reddy PNG, Sullivan JD, Walter MJ, Zou L, Graubert TA. Spliceosome mutations induce R Loop-Associated sensitivity to ATR Inhibition in myelodysplastic syndromes. Cancer Res. 2018;78:5363\u201374.","journal-title":"Cancer Res"},{"key":"763_CR77","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3324\/haematol.2020.254193","volume":"106","author":"J Flach","year":"2021","unstructured":"Flach J, Jann J-C, Knaflic A, et al. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations. Haematologica. 2021;106:2906\u201317.","journal-title":"Haematologica"},{"key":"763_CR78","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2013.04.028","volume":"153","author":"X Ji","year":"2013","unstructured":"Ji X, Zhou Y, Pandit S, Huang J, Li H, Lin CY, Xiao R, Burge CB, Fu X-D. SR proteins collaborate with 7SK and Promoter-Associated nascent RNA to release paused polymerase. Cell. 2013;153:855\u201368.","journal-title":"Cell"},{"key":"763_CR79","doi-asserted-by":"publisher","first-page":"114869","DOI":"10.1016\/j.celrep.2024.114869","volume":"43","author":"RE Wagner","year":"2024","unstructured":"Wagner RE, Arnetzl L, Britto-Borges T, et al. SRSF2 safeguards efficient transcription of DNA damage and repair genes. Cell Rep. 2024;43:114869.","journal-title":"Cell Rep"},{"key":"763_CR80","doi-asserted-by":"publisher","first-page":"142149","DOI":"10.1172\/jci.insight.142149","volume":"6","author":"Z Tothova","year":"2021","unstructured":"Tothova Z, Valton A-L, Gorelov RA, et al. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS\/AML. JCI Insight. 2021;6:142149.","journal-title":"JCI Insight"},{"key":"763_CR81","doi-asserted-by":"publisher","first-page":"eade2774","DOI":"10.1126\/scitranslmed.ade2774","volume":"16","author":"EC Wheeler","year":"2024","unstructured":"Wheeler EC, Martin BJE, Doyle WC, et al. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Sci Transl Med. 2024;16:eade2774.","journal-title":"Sci Transl Med"},{"key":"763_CR82","doi-asserted-by":"crossref","unstructured":"Network TCGAR. Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","DOI":"10.1056\/NEJMoa1301689"},{"key":"763_CR83","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","volume":"64","author":"C Cretu","year":"2016","unstructured":"Cretu C, Schmitzov\u00e1 J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, Will CL, Urlaub H, L\u00fchrmann R, Pena V. Molecular architecture of SF3b and structural consequences of its Cancer-Related mutations. Mol Cell. 2016;64:307\u201319.","journal-title":"Mol Cell"},{"key":"763_CR84","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","volume":"24","author":"M Seiler","year":"2018","unstructured":"Seiler M, Yoshimi A, Darman R, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497\u2013504.","journal-title":"Nat Med"},{"key":"763_CR85","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","volume":"35","author":"E Wang","year":"2019","unstructured":"Wang E, Lu SX, Pastore A, et al. Targeting an RNA-Binding protein network in acute myeloid leukemia. Cancer Cell. 2019;35:369\u2013e3847.","journal-title":"Cancer Cell"},{"key":"763_CR86","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41594-019-0313-z","volume":"26","author":"A Radzisheuskaya","year":"2019","unstructured":"Radzisheuskaya A, Shliaha PV, Grinev V, Lorenzini E, Kovalchuk S, Shlyueva D, Gorshkov V, Hendrickson RC, Jensen ON, Helin K. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat Struct Mol Biol. 2019;26:999\u20131012.","journal-title":"Nat Struct Mol Biol"},{"key":"763_CR87","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","volume":"53","author":"JW Hwang","year":"2021","unstructured":"Hwang JW, Cho Y, Bae G-U, Kim S-N, Kim YK. Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med. 2021;53:788\u2013808.","journal-title":"Exp Mol Med"},{"key":"763_CR88","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood-2019-131559","volume":"134","author":"A Yoda","year":"2019","unstructured":"Yoda A, Morishita D, Mizutani A, Satoh Y, Ochi Y, Nannya Y, Makishima H, Miyake H, Ogawa S. CTX-712, a novel Clk inhibitor targeting myeloid neoplasms with SRSF2 mutation. Blood. 2019;134:404.","journal-title":"Blood"},{"key":"763_CR89","first-page":"1","volume":"8","author":"M Song","year":"2023","unstructured":"Song M, Pang L, Zhang M, Qu Y, Laster KV, Dong Z. Cdc2-like kinases: structure, biological function and therapeutic targets for diseases. Signal Transduct Target Ther. 2023;8:1\u201325.","journal-title":"Signal Transduct Target Ther"},{"key":"763_CR90","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","volume":"26","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM, Ridinger M, Lin TL, et al. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:6132\u201340.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"763_CR91","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","volume":"35","author":"DP Steensma","year":"2021","unstructured":"Steensma DP, Wermke M, Klimek VM, et al. Phase I First-in-Human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35:3542\u201350.","journal-title":"Leukemia"},{"key":"763_CR92","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","volume":"37","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, Stahl M, Taylor J, et al. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 2023;37:2512\u20136.","journal-title":"Leukemia"},{"key":"763_CR93","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/cncr.31398","volume":"124","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Kadia TM, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018;124:2758\u201365.","journal-title":"Cancer"},{"key":"763_CR94","doi-asserted-by":"publisher","first-page":"204062072412753","DOI":"10.1177\/20406207241275376","volume":"15","author":"J Watts","year":"2024","unstructured":"Watts J, Minden MD, Bachiashvili K, et al. Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms. Ther Adv Hematol. 2024;15:20406207241275376.","journal-title":"Ther Adv Hematol"},{"key":"763_CR95","doi-asserted-by":"publisher","first-page":"107390","DOI":"10.1016\/j.leukres.2023.107390","volume":"134","author":"T Haque","year":"2023","unstructured":"Haque T, Cadenas FL, Xicoy B, et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leuk Res. 2023;134:107390.","journal-title":"Leuk Res"},{"key":"763_CR96","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41375-025-02515-8","volume":"39","author":"JP Bewersdorf","year":"2025","unstructured":"Bewersdorf JP, Mi X, Lu B, et al. Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Leukemia. 2025;39:765\u20139.","journal-title":"Leukemia"},{"key":"763_CR97","doi-asserted-by":"crossref","unstructured":"Abstract CT115: A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort | Cancer Research | American Association for Cancer Research. https:\/\/aacrjournals.org\/cancerres\/article\/84\/7_Supplement\/CT115\/742613\/Abstract-CT115-A-first-in-human-phase-I-study-of. Accessed 18 May 2025","DOI":"10.1158\/1538-7445.AM2024-CT115"},{"key":"763_CR98","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","volume":"40","author":"G Garcia-Manero","year":"2022","unstructured":"Garcia-Manero G, Winer ES, DeAngelo DJ, et al. Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome. J Clin Oncol. 2022;40:7016\u20137016.","journal-title":"J Clin Oncol"},{"key":"763_CR99","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1182\/blood-2021-147301","volume":"138","author":"AM Brunner","year":"2021","unstructured":"Brunner AM, Liu Y, Mendez LM, et al. Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib\/II Study. Blood. 2021;138:1521.","journal-title":"Blood"},{"key":"763_CR100","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2024-195793","volume":"144","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, Liu Y, Garcia JS, et al. Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy. Blood. 2024;144:1833.","journal-title":"Blood"},{"key":"763_CR101","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","volume":"12","author":"RM Carr","year":"2021","unstructured":"Carr RM, Vorobyev D, Lasho T, et al. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021;12:2901.","journal-title":"Nat Commun"},{"key":"763_CR102","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s00277-023-05442-9","volume":"102","author":"PJP Croucher","year":"2023","unstructured":"Croucher PJP, Ridinger M, Becker PS, Lin TL, Silberman SL, Wang ES, Zeidan AM. Spliceosome mutations are associated with clinical response in a phase 1b\/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Ann Hematol. 2023;102:3049\u201359.","journal-title":"Ann Hematol"},{"key":"763_CR103","doi-asserted-by":"crossref","unstructured":"McCullough K, Mangaonkar AA, Burgess AR, et al (2023) Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed\/refractory or intolerant to available therapies. J Clin Oncol 41:TPS7089\u2013TPS7089","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7089"},{"key":"763_CR104","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","volume":"38","author":"S Shimony","year":"2024","unstructured":"Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M, Neuberg DS, DeAngelo DJ, Stone RM, Lindsley RC. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia. 2024;38:1494\u2013500.","journal-title":"Leukemia"},{"key":"763_CR105","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","volume":"41","author":"E Wang","year":"2023","unstructured":"Wang E, Pineda JMB, Kim WJ, et al. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell. 2023;41:164-180.e8.","journal-title":"Cancer Cell"},{"key":"763_CR106","doi-asserted-by":"publisher","first-page":"100107","DOI":"10.1016\/j.bneo.2025.100107","volume":"2","author":"M Liu","year":"2025","unstructured":"Liu M, Yan M, Davis AG, Stoner SA, Ball ED, Zhang D-E. Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML. Blood Neoplasia. 2025;2:100107.","journal-title":"Blood Neoplasia"},{"key":"763_CR107","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"763_CR108","doi-asserted-by":"publisher","unstructured":"Diamantidis MD. Factors affecting response and resistance to venetoclax in acute myeloid leukemia. Front Oncol. 2025. https:\/\/doi.org\/10.3389\/fonc.2025.1577908.","DOI":"10.3389\/fonc.2025.1577908"},{"key":"763_CR109","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.trecan.2024.10.008","volume":"11","author":"A Rosenberg-Mogilevsky","year":"2025","unstructured":"Rosenberg-Mogilevsky A, Siegfried Z, Karni R. Generation of tumor neoantigens by RNA splicing perturbation. Trends Cancer. 2025;11:12\u201324.","journal-title":"Trends Cancer"},{"key":"763_CR110","doi-asserted-by":"publisher","unstructured":"Kim WJ, Crosse EI, De Neef E, et al. Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell. 2025. https:\/\/doi.org\/10.1016\/j.cell.2025.03.047.","DOI":"10.1016\/j.cell.2025.03.047"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00763-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00763-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00763-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:03:20Z","timestamp":1769051000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00763-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00763-0","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nickolas Steinauer declares that he has no conflict of interest. Mrinal M. Patnaik has received research funding from Kura Oncology, Stem Line Pharmaceuticals, Epigenetix, Polaris, and Solu Therapeutics. He has served on the advisory board for GSK, AstraZeneca and SOBI pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"16"}}